Brief: Nicox Says Ocumension Get Positive Phase 3 Clinical Trial Results For Zerviate In China

Ocumension Therapeutics

01/03/2022 06:34

March 1 (Reuters) - Nicox SA  NCOX.PA :
    * REG-NICOX’S PARTNER OCUMENSION OBTAINS POSITIVE PHASE 3
CLINICAL
TRIAL RESULTS FOR ZERVIATE® IN CHINA
    * ZERVIATE (CETIRIZINE OPHTHALMIC SOLUTION), 0.24% WAS
NON-INFERIOR TO COMPARATOR EMEDASTINE DIFUMARATE OPHTHALMIC
SOLUTION, 0.05%
    * ZERVIATE WAS SAFE AND WELL-TOLERATED WITH NO DIFFERENCE IN
PROPORTION OF PATIENTS WITH ADVERSE EVENTS COMPARED TO
EMEDASTINE DIFUMARATE
    * CLINICAL TRIAL IS REQUIRED FOR OCUMENSION TO BE ABLE TO
SUBMIT A
NEW DRUG APPLICATION (NDA) FOR APPROVAL TO COMMERCIALIZE
ZERVIATE IN CHINA

Source text for Eikon:  ID:nGNE6ZBGP3 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))